Plain-English translation of NCT06891703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing a new imaging agent called [18F]ACI-15916 that can help detect abnormal protein deposits in the brain using a type of scan called PET. This is the first time this agent is being used in humans. The study will involve up to 46 participants—some with diagnoses like Parkinson's disease or related conditions, and some who are healthy—to see if the medication works safely and reliably for detecting these protein deposits.
Currently, there is no reliable way to image the specific protein deposits (called alpha-synuclein) that build up in Parkinson's disease and similar conditions while patients are alive. A better imaging tool could help doctors diagnose these diseases earlier and track how they progress, which might lead to better treatments.
You likely qualify if…
You likely don't qualify if…
Your participation will last 10–14 weeks depending on which part of the study you join. You'll have a screening visit (up to 60 days before the scan), then come for a brain imaging scan where you'll receive the study medication and may have blood samples taken from an artery. Some participants will return for a second scan within one month to test how reliable the imaging is. You'll also receive a safety phone call after each visit.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Sweden